Lupin 2024

Lumify

Dr. Reddy’s acquires rights to private label Lumify

Dr. Reddy’s acquires rights to private label Lumify

PRINCETON, N.J. – Dr. Reddy’s Laboratories has acquired U.S. rights to Slayback Pharma’s brimonidine tartrate ophthalmic solution 0.025%, the private label equivalent of Lumify. The-counter eye drop can be used to relieve redness due to minor eye irritations. The agreement also provides Dr. Reddy’s exclusive rights to the product outside the U.S. Slayback is the

Bausch + Lomb receives Health Canada approval for Lumify

Bausch + Lomb receives Health Canada approval for Lumify

VAUGHAN, ON — Bausch + Lomb Corp. announced that Health Canada has approved Lumify (brimonidine tartrate ophthalmic solution 0.025% w/v), the first and only over-the-counter (OTC) eye drop developed with low-dose brimonidine tartrate to relieve redness of the eye due to minor eye irritations for adults. “With Health Canada’s approval of Lumify, we are excited

LUMIFY makes Nielsen’s BASES innovations list

LUMIFY makes Nielsen’s BASES innovations list

BRIDGEWATER, N.J.  – Bausch + Lomb announced that BASES, a Nielsen Global Consumer business division, has named LUMIFY (brimonidine tartrate ophthalmic solution 0.025%) redness reliever eye drops to its 2020 U.S. BASES Top 25 Breakthrough Innovations List in the “Superstar” category for its success in driving sales and category growth. The Top 25 Breakthrough Innovations

LUMIFY picks up Product Showcase award at TSE

LUMIFY picks up Product Showcase award at TSE

RIDGEWATER, N.J. — Bausch + Lomb announced that LUMIFY brimonidine tartrate ophthalmic solution 0.025% redness reliever eye drops were named a Product Showcase winner in the healthcare and over-the-counter (OTC) category at the National Association of Chain Drug Stores’ (NACDS) 2018 Total Store Expo. “We’re honored to be recognized by NACDS with the coveted Product Showcase award

PP_1170x120_10-25-21